Redirecting innate cells to kill cancer

Immuno-oncology company Affimed is harnessing the power of innate immunity, with the help of its ROCK (Redirected Optimized Cell Killing) platform to change the lives of patients with cancer

Go to the profile of Affimed
Mar 17, 2020
0
0
Page of
Go to the profile of Affimed

Affimed

Executive, Affimed

ffimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK® platform allows innate cell engagers to be designed for specific patient populations. The Company is developing single and combination therapies to treat hematologic and solid tumors. For more information, please visit www.affimed.com.

No comments yet.